tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IBRX Stock Latest News

ImmunityBio announces approval in Macau for Anktiva
The FlyImmunityBio announces approval in Macau for Anktiva
1d ago
IBRX
Mixed options sentiment in ImmunityBio with shares up 3.53%
PremiumThe Fly
Mixed options sentiment in ImmunityBio with shares up 3.53%
3d ago
IBRX
Buy Rating on ANKTIVA: NCCN Guideline Expansion, Off‑Label Upside, and DCF‑Backed Risk‑Reward in BCG‑Unresponsive NMIBC
PremiumRatings
Buy Rating on ANKTIVA: NCCN Guideline Expansion, Off‑Label Upside, and DCF‑Backed Risk‑Reward in BCG‑Unresponsive NMIBC
4d ago
IBRX
Expanding ANKTIVA’s NMIBC Opportunity: NCCN Endorsement, FDA Flexibility, and Strengthening Long‑Term Prospects for ImmunityBio
PremiumRatings
Expanding ANKTIVA’s NMIBC Opportunity: NCCN Endorsement, FDA Flexibility, and Strengthening Long‑Term Prospects for ImmunityBio
4d ago
IBRX
ImmunityBio announces NCCN Guidelines for Bladder Cancer to include Anktiva
PremiumThe Fly
ImmunityBio announces NCCN Guidelines for Bladder Cancer to include Anktiva
5d ago
IBRX
Mixed options sentiment in ImmunityBio with shares down 2.26%
PremiumThe FlyMixed options sentiment in ImmunityBio with shares down 2.26%
5d ago
IBRX
Morning Movers: Adobe falls with Narayen set to exit as CEO
Premium
The Fly
Morning Movers: Adobe falls with Narayen set to exit as CEO
8d ago
KLC
NIO
ImmunityBio reports 64 subjects complete apheresis collection in NK2022, NK2023
Premium
The Fly
ImmunityBio reports 64 subjects complete apheresis collection in NK2022, NK2023
9d ago
IBRX
ImmunityBio assumed with a Buy at BTIG
PremiumThe Fly
ImmunityBio assumed with a Buy at BTIG
10d ago
IBRX
Buy Rating on ImmunityBio Driven by ANKTIVA’s Rapid Commercial Ramp, Global Expansion, and Pipeline Catalysts
PremiumRatings
Buy Rating on ImmunityBio Driven by ANKTIVA’s Rapid Commercial Ramp, Global Expansion, and Pipeline Catalysts
10d ago
IBRX
ImmunityBio Earnings Call: ANKTIVA Surge Amid High Burn
PremiumCompany Announcements
ImmunityBio Earnings Call: ANKTIVA Surge Amid High Burn
11d ago
IBRX
Moderately bullish activity in ImmunityBio with shares down 5.71%
PremiumThe Fly
Moderately bullish activity in ImmunityBio with shares down 5.71%
12d ago
IBRX
ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG
PremiumThe FlyImmunityBio resubmits sBLA to FDA for Anktiva plus BCG
13d ago
IBRX
Mixed options sentiment in ImmunityBio with shares down 10.25%
Premium
The Fly
Mixed options sentiment in ImmunityBio with shares down 10.25%
17d ago
IBRX
ImmunityBio price target raised to $12 from $7 at Piper Sandler
Premium
The Fly
ImmunityBio price target raised to $12 from $7 at Piper Sandler
17d ago
IBRX
ImmunityBio: Advancing ANKTIVA Into a Global, Multi-Indication Immunotherapy Platform Supporting a Buy Rating and $15 Target
PremiumRatings
ImmunityBio: Advancing ANKTIVA Into a Global, Multi-Indication Immunotherapy Platform Supporting a Buy Rating and $15 Target
18d ago
IBRX
IBRX Earnings this Week: How Will it Perform?
PremiumPre-Earnings
IBRX Earnings this Week: How Will it Perform?
21d ago
IBRX
ImmunityBio completes enrollment of Anktiva trial
PremiumThe Fly
ImmunityBio completes enrollment of Anktiva trial
23d ago
IBRX
ImmunityBio price target raised to $15 from $10 at H.C. Wainwright
PremiumThe Fly
ImmunityBio price target raised to $15 from $10 at H.C. Wainwright
26d ago
IBRX
ImmunityBio rises 14.7%
PremiumThe FlyImmunityBio rises 14.7%
26d ago
IBRX
ImmunityBio rises 25.2%
Premium
The Fly
ImmunityBio rises 25.2%
26d ago
IBRX
ImmunityBio reports Q4 EPS (6c), consensus (10c)
Premium
The Fly
ImmunityBio reports Q4 EPS (6c), consensus (10c)
27d ago
IBRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >